Prenatal Opioid Risks: A new review links prenatal opioid exposure to worse vision, more attention and hyperactivity problems, and lower cognitive performance in children. Gender-Affirming Care Access: Penn State Health stopped providing certain care for a transgender teen, citing federal directives after a Trump executive order, forcing a switch to a new doctor. Pharma Mega-Merger Buzz: AstraZeneca and Bristol Myers Squibb held early talks about a possible merger, but investors and analysts flag major overlap and antitrust hurdles. Leadership Shake-Up at BioNTech/Sobi: BioNTech appointed Sobi CEO Guido Oelkers as incoming CEO, while Sobi confirmed his step-down. US Antitrust Settlements: Sandoz agreed to pay $450m to settle US state antitrust claims tied to alleged price-fixing. Cybersecurity in Biopharma: Amgen disclosed a cybersecurity breach with patient health information potentially exfiltrated from cloud storage. Healthcare Policy/Access: India’s hospital groups pushed back on insurer guidance for fever admissions, saying clinical judgment should drive decisions. Clinical Care Evidence: UK trial results suggest compression wraps may heal venous leg ulcers more slowly than established evidence-based options. Rare Disease Trial Move: Can-Fite submitted a Phase 2 protocol to test piclidenoson for Lowe syndrome at Bambino Gesù Children’s Hospital. 340B Compliance Focus: HealthTrust held its 340B Summit amid proposed rebate model changes, contract pharmacy restrictions, and audit scrutiny.